HLB Therapeutics Co Ltd
115450
Company Profile
Business description
HLB Therapeutics Co Ltd is a biotech company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a biopharmaceutical company focused on alleviating patient suffering.
Contact
22F, Parkview Tower
6, Jeongja-Dong, Bundang-Gu
Seongnam-si463-811
KORT: +82 317867800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
95
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,188.11 | 107.70 | -0.24% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,463.15 | 183.52 | 0.86% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,439.26 | 23.72 | 0.37% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |